BIRCHVIEW CAPITAL LP
Q3 2026 Form 13-F

BURLINGTON, VERMONT
CIK 0001618205 · CRD 170534 · SEC-registered investment adviser
$173.1M Reported Value Total

BIRCHVIEW CAPITAL, LP reports 16 total accounts under management (AUM). There are 16 discretionary accounts valued at $239,112,096, and 0 non-discretionary accounts.

Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered Discretionary Manager
Private funds (Form ADV)
13 funds · $112.3M gross asset value
Hedge Fund: $97.5M · Private Equity Fund: $14.7M
Source: Form ADV filed 2026-10-13
Reported value
$173.1M
Quarter over quarter
-15.4%
Holdings
79
Top-10 concentration
56.0%

Key People

Form ADV owners & control persons
Matthew William Strobeck
CHIEF EXECUTIVE OFFICER AND MANAGING PARTNER
Nicholas Renegar
DIRECTOR OF QUANT STRATEGIES
Benjamin Grant Small
CHIEF OPERATING OFFICER

Filing Navigation

13F Metrics

Loading 13F Metrics

Q3 2026 13F record

Q3 2026 13F filing summary

Q3 2026 Form 13F portfolio summary
Period of report September 30, 2026
Filed November 13, 2026
Form 13F-HR
Reported value $173.1M
Positions 79
Change in reported value -19.0%
New positions 23
Exited positions 16
Position turnover 41.1%
Top-10 concentration 56.0%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q3 2026 13F
Filed Nov 13, 2026
79 $173.1M
Q2 2026 13F
Filed Aug 14, 2026
72 $213.8M
Q1 2026 13F
Filed May 15, 2026
73 $175.7M
Q4 2025 13F
Filed Feb 13, 2026
68 $170.8M
Q3 2025 13F
Filed Nov 13, 2025
69 $132.4M
Q2 2025 13F
Filed Aug 14, 2025
71 $100.7M
Q1 2025 13F
Filed May 15, 2025
68 $115.2M
Q4 2024 13F
Filed Feb 14, 2025
68 $122.9M
Q3 2024 13F
Filed Nov 14, 2024
61 $115.5M
Q2 2024 13F
Filed Aug 13, 2024
60 $108.2M
Q1 2024 13F
Filed May 14, 2024
59 $122.7M
Q4 2023 13F
Filed Feb 14, 2024
58 $127.8M
Q3 2023 13F
Filed Nov 14, 2023
51 $117.7M
Q2 2023 13F
Filed Aug 8, 2023
54 $133.4M
Q1 2023 13F
Filed May 12, 2023
55 $127.7M
Q4 2022 13F
Filed Feb 3, 2023
57 $141.6M
Q3 2022 13F
Filed Nov 7, 2022
60 $142.0M
Q2 2022 13F
Filed Aug 12, 2022
60 $137.5M
Q1 2022 13F
Filed May 13, 2022
63 $138.9M
Q4 2021 13F
Filed Feb 14, 2022
67 $155.1M

28 earlier quarters on file — choose one from the quarter menu above.

Top 20 holdings · Q3 2026

Largest Q3 2026 13F positions by reported value
# Holding Reported value % of portfolio
1 KLAC KLA CORPORATION $32.5M 18.8%
2 BMY BRISTOL-MYERS SQUIBB CO $14.0M 8.08%
3 LRCX LAM RESEARCH CORPORATION $9.9M 5.69%
4 BDSXXXXX BIODESIX INC $8.6M 4.94%
5 CORT CORCEPT THERAPEUTICS INC $6.4M 3.67%
6 OVV OVINTIV INC $6.2M 3.59%
7 RARE ULTRAGENYX PHARMACEUTICAL INC $5.6M 3.24%
8 SLDB SOLID BIOSCIENCES INC $5.2M 2.99%
9 PTGX PROTAGONIST THERAPEUTICS INC $4.9M 2.85%
10 PRTA PROTHENA CORP PLC $3.8M 2.17%
11 HALO HALOZYME THERAPEUTICS INC $3.7M 2.13%
12 STOK STOKE THERAPEUTICS INC $3.6M 2.07%
13 NBIX NEUROCRINE BIOSCIENCES INC $3.6M 2.06%
14 ACAD ACADIA PHARMACEUTICALS INC $3.4M 1.99%
15 NTLA INTELLIA THERAPEUTICS INC $3.4M 1.96%
16 NKTR NEKTAR THERAPEUTICS $2.8M 1.61%
17 VIR VIR BIOTECHNOLOGY INC $2.5M 1.47%
18 ZBIO ZENAS BIOPHARMA INC $2.5M 1.45%
19 21217B950 CONTINEUM THERAPEUTICS INC (CTNM) P @ 15.0 01/15/2027 $2.3M 1.31%
20 ABVX ABIVAX SA $2.1M 1.2%

Values as reported on the Q3 2026 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings